Cartesian Therapeutics Inc. (RNAC) — Cash Flow Quality Index
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Quality Index of -1.10x as of June 2025. Operating cash flow of $-17.52 Million is below net income of $15.89 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore RNAC cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cartesian Therapeutics Inc. Cash Flow Quality Index (2022–2022)
Historical Cash Flow Quality Index for Cartesian Therapeutics Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check RNAC cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Cartesian Therapeutics Inc. (2022–2022)
Year-by-year earnings quality comparison for Cartesian Therapeutics Inc.. For live market cap and the full company financial profile, see RNAC stock market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | -0.89x | $-31.63 Million | $35.38 Million | — |